The 11q13 region is amplified in approximately 15% of all breast tumors. Situated in this region are the cyclin D1 gene (CCND1) and the p-21-activated kinase 1 (PAK1) gene. Both genes encode proteins shown to activate the estrogen receptor (ER), leading to transcription of CCND1 and other ER-responsive genes. Here, we investigate the prognostic and treatment predictive role of CCND1 and PAK1 gene amplification in postmenopausal breast cancer patients randomized to tamoxifen treatment or no adjuvant treatment. Amplification of CCND1 and PAK1, assessed by real-time PCR, was observed in 12.5 and 9.3%, respectively. Amplification of PAK1 was seen in 37% of the CCND1-amplified tumors, indicating coamplification (Po0.001). In ER-positive patients, amplification of at least one of the genes indicated a reduced recurrence-free survival (P=0.025). When response to tamoxifen treatment was analysed, patients with PAK1 amplification showed decreased benefit from the drug (ER+; relative risk ratio (RR)=1.62; 95% confidence interval (CI), 0.47-5.55) compared to patients without amplification (ER+; RR=0.53; 95% CI, 0.32-0.88). This was not evident for CCND1 amplification. We show that PAK1 may be a predictor of tamoxifen resistance and furthermore, we do not discard PAK1 as a potential candidate oncogene in the 11q13 amplicon. In addition, we show that high pak1 protein levels may predict tamoxifen insensitivity.
Introduction
Amplification of oncogenes is a common nonrandom cellular event for driving tumorigenesis. Chromosome 11 harbors a gene-rich region, 11q13, which is amplified in approximately 15% of primary human breast cancers (Karlseder et al., 1994; Ormandy et al., 2003) . The high frequency implies that the region contains oncogenes that more or less contribute to positive selection for cell proliferation and survival. Several distinct core regions within the 11q13 amplicon have been shown to be amplified independent of one another. Karlseder et al. (1994) suggest four or more candidate oncogenes. Recently, up to eight cores have been suggested for this region (Albertson, 2006) .
The far most studied oncogene in the region is the CCND1 gene that encodes the cell-cycle regulatory protein cyclin D1. Apart from driving the cell-cycle progression in G 1 phase, cyclin D1 has cdk-independent functions. One interesting role is ligand-independent activation of the estrogen receptor a (ERa) through direct binding, which possibly could induce anti-estrogen insensitivity (Zwijsen et al., 1997 (Zwijsen et al., , 1998 Bernards, 1999; Fu et al., 2004) . Experimental studies show that the CCND1 gene is a transcriptional target of active ERa. Anti-estrogen treatment of the breast cancer cell line MCF-7 decreased the expression of cyclin D1 and cells eventually entered a G 0 -like state (Doisneau-Sixou et al., 2003) .
The gene encoding p-21-activated kinase 1 (pak1) has recently been added to the list of major candidate oncogenes within the 11q13 amplicon. Pak1 is a serine/ threonine kinase with impact on many aspects of normal mammary epithelial cells, such as cytoskeletal structure, motility and mitosis (Vadlamudi et al., 2000 (Vadlamudi et al., , 2005 Li et al., 2002) . Involvement of pak1 in mammary tumor development and progression is under investigation. Hitherto, overexpression of the protein has been suggested to influence mammary hyperplasia, malignancy, and more specific; anchorage-independent growth, invasiveness and cell survival (Vadlamudi et al., 2000; Jin et al., 2005; Menard et al., 2005; Wang et al., 2006) . Pak1 activates the ERa by phosphorylating serine 305 in the ligand-dependent domain of the receptor leading to transcription of ERa-responsive genes such as the CCND1 gene (Wang et al., 2002) .
The pak1 pathway, starting at the cell surface by growth factor activation of receptors, could also influence cyclin D1 oncogenic functions in breast cancer through an NF-kB-dependent pathway (Balasenthil et al., 2004b) .
The benefit from adjuvant therapy with the antiestrogen tamoxifen in ERa-positive breast cancer is widely accepted, significantly reducing recurrence risk and prolonging survival. Ligand-dependent activation of the ERa is inhibited in a competitive manner. Several patients do not respond to tamoxifen treatment and relapse, indicating resistance to the drug (Ali and Coombes, 2002) . The mechanisms for resistance are under investigation, but far from unraveled. An important issue is to identify subgroups of breast cancer patients who will not respond to adjuvant tamoxifen treatment.
Given the suggested role of CCND1 and PAK1 as oncogenes with possible importance for tamoxifen response, we investigated the prognostic and treatment predictive significance of CCND1 and PAK1 gene amplification in postmenopausal breast cancer patients randomized to adjuvant tamoxifen treatment or no tamoxifen treatment (Rutqvist and Johansson, 2006) . In addition, pak1 protein expression was analysed with immunohistochemistry in a subset of tumors.
Results
Gene amplification analysis of the PAK1 and CCND1 genes was performed by using real-time PCR in 214 and 224 tumors, respectively. Amplification of PAK1 was observed in 9.3% (20/214) and amplification of CCND1 could be detected in 12.5% (28/224). Amplification of the PAK1 gene was detected in 37% (10/27) of the CCND1-amplified tumors. Amplification of the genes correlated significantly with positive ER status. Ninety Table 1 Correlations between PAK1, CCND1, 11q13 amplification (PAK1 and/or CCND1) and clinicopathological parameters in postmenopausal breast carcinomas (Figure 1 ). Multivariate analysis showed that 11q13 amplification had independent prognostic value ( Table 2) .
Amplification and tamoxifen response
Benefit from tamoxifen, with RFS as end point, could be detected in patients with ER-positive tumors carrying no CCND1 gene amplification (P ¼ 0.05) or no PAK1 gene amplification (P ¼ 0.013), whereas no significant benefit could be seen in patients with CCND1 amplification (P ¼ 0.28) or with PAK1 gene amplification (P ¼ 0.43) ( Figure 2 ). Analysing the two genes together gives an indication of 11q13 amplification in general. Patients with tumors carrying no 11q13 amplification showed benefit from tamoxifen treatment (P ¼ 0.05), whereas tamoxifen-treated patients with 11q13-amplified tumors relapsed to almost a similar extent as the control group (P ¼ 0.49). However, only PAK1 amplification interacted significantly with the benefit of tamoxifen treatment (P ¼ 0.03) ( Table 3) .
Protein expression
Immunohistochemical staining of pak1 was performed in 101 tumors of which 65 were negative or weak and 36 showed moderate or strong cytoplasmic staining. Tumors were also evaluated for nuclear staining intensity where 69 were negative or weak and 32 were moderate or strong. The former groups were considered normal and the latter groups were considered overexpressed ( Figure 3 ). Pak1 cytoplasmic staining correlated well with nuclear staining (Po0.0001). Nuclear staining was observed as a dotted pattern. One hundred and ninetyfive tumors were available for cyclin D1 protein to gene status analysis, whereas only 86 samples were available for pak1 protein to gene status analysis. No significant correlations were found between gene amplification and overexpression of the corresponding protein; cyclin D1 nuclear staining (P ¼ 0.39), pak1 cytoplasmic staining (P ¼ 0.80) or nuclear staining (P ¼ 0.72). However, pak1 protein to gene analysis included few tumors with PAK1 amplification (Table 1) . Neither pak1 protein expression in cytoplasm, nor in nucleus, correlated with cyclin D1 protein expression (data not shown). Analysing RFS in the whole population with respect to pak1 staining intensity showed no significant difference between patients with negative/weak cytoplasmic staining and patients with moderate/strong staining (overexpressed versus normal; RR ¼ 0.92; 95% CI, 0.65-1.31, P ¼ 0.92).
Nor could any significant difference be observed when comparing patients with nuclear pak1 negative/weak staining to patients showing nuclear pak1 moderate/ strong staining (overexpressed versus normal; RR ¼ 0.79; 95% CI, 0.43-1.44, P ¼ 0.97). Pak1 protein expression and tamoxifen sensitivity Analyses of cytoplasmic pak1 staining showed that tamoxifen-treated ER-positive patients with low pak1 expression showed benefit from the drug compared to the non-treated control group (P ¼ 0.01), whereas patients with moderate or strong pak1 cytoplasmic protein expression showed similar relapse frequency as the control group (P ¼ 0.70). A similar trend could be observed for pak1 nuclear staining intensity (Figure 4 ). However, no significance could be detected in the test for interaction with tamoxifen benefit (Table 3) .
Discussion
This is the first study to analyse PAK1 and CCND1 amplification together in a large series of primary breast cancer. We found CCND1 and PAK1 to be amplified in 12.5 and 9.3%, respectively. To some extent, the two genes were coamplified and at least one of the genes was amplified in 17.5%. Genomic instability may be reflected by 11q13 amplification in breast tumors (Bie`che et al., 2002) . These chromosomal changes are also present in DNA diploid cells and ductal carcinoma in situ (Rennstam et al., 2001) , suggesting that amplification in this region is an early event. Jirstro¨m et al., 2005) . Specific gene copy number gain of the PAK1 gene has earlier been reported in small groups of breast (Bekri et al., 1997) and ovarian cancers (Schraml et al., 2003; Brown et al., 2006; Mayr et al., 2006) . We found PAK1 gene amplification in 37% of the tumor samples carrying CCND1 gene amplification, indicating a high frequency of coamplification. The two 11q13 amplification and tamoxifen in breast cancer J Bostner et al genes are found about 7.5 Mb apart in a region with several amplicon cores and the genes are situated in each end of the region, where the CCND1 is closer to the centrosome.
In this study, we show increased recurrence risk for patients with ER-positive tumors with gene amplification in the 11q13 region. This is in agreement with Bie`che et al. (2002) who compared CCND1 amplification status to RFS and also in agreement with Champeme et al. (1995) , who analysed amplification status of the 11q13 region in relation to the same end point. Furthermore, we observed an increase in recurrence risk for patients with CCND1 gene amplification compared to non-amplified.
We demonstrate very strong correlation between gene amplification in 11q13 and ER status. This is in line with previous gene copy number studies done on this chromosomal region in breast cancer (Fantl et al., 1990; Bie`che et al., 2002; Jirstro¨m et al., 2005) . Also amplification of the AIB1 gene, encoding an ER coactivator, on chromosome 20 has been found exclusively in ER-positive tumors (Wong et al., 2006) . This indicates that amplification of the assessed genes confers selective advantage in the tumorigenesis of ERpositive breast cancer. Several studies show that the pak1 protein interacts with the ER (Wang et al., 2002; Balasenthil et al., 2004a; Rayala et al., 2006b) . Also, the cyclin D1 protein has been shown to form a complex with the ER and thereby activating its transactivating functions in the absence of estradiol (Neuman et al., 1997) . Additional evidence for this theory is the reported low frequency of 11q13 amplification in several malignancies except for breast cancer, ovarian cancer and head and neck squamous-cell carcinoma (Schuuring, 1995) . We suggest that the 11q13 amplicon drives tumorigenesis partly through activation of the ER. There are a number of uninvestigated genes in the 11q13 chromosomal region, but no other genes apart from the CCND1 and the PAK1 genes have hitherto shown close relation to the ER and tamoxifen response in breast cancer.
Experimental studies have recently shown increasing evidence for the cyclin D1 and pak1 connection to tamoxifen response (Hodges et al., 2003; Holm et al., 2006; Rayala et al., 2006b) . For that reason, we sought to analyse the association of these two genes with tamoxifen resistance in a clinical material. Jirstro¨m et al. (2005) suggested an agonistic effect of tamoxifen in CCND1-amplified premenopausal breast tumors. We studied both the CCND1 gene amplification status and the PAK1 gene amplification status in ER-positive postmenopausal breast tumors. The results indicate that tamoxifen may have an agonistic effect on PAK1-amplified tumors, whereas CCND1-amplified tumors only showed a tendency toward decreased tamoxifen sensitivity. Worth noting though is that the statistical power of this analysis is limited because of the small number of cases in the gene-amplified subgroups. The choice of cutoff level can be crucial when using real-time PCR; however, analyses of tamoxifen response using cutoff levels ranging from 1.5 to 2.0 for PAK1 amplification showed similar levels of significance (data not shown).
Pak1 protein has been shown to contain a nuclear localization signal and apart from ER phosphorylation additional nuclear functions have been suggested (Singh et al., 2005) . The protein has been shown to phosphorylate histone H3.3a and thereby controlling gene expression and it may also influence mitotic events (Li et al., 2002; Vadlamudi et al., 2005) . We observed spotted pak1 pattern within the nucleus. This has earlier been suggested to indicate an association with mitotic chromosomes during prophase (Rayala et al., 2006a) . No correlation between pak1 staining intensity and S-phase fraction was found in this study. This is in contrast to results presented by Holm et al. (2006) , where both cytoplasmic and nuclear overexpression was associated with high expression of the proliferation marker Ki-67. Neither could any correlation between cyclin D1 staining intensity and proliferation be detected in our study (data not shown). In agreement with Holm et al. (2006) , we observed no link between pak1 overexpression and RFS in univariate analysis. Also in line with Holm et al. (2006) , patients with overexpressed pak1 show decreased response to tamoxifen.
Recent results presented on premenopausal breast cancer, showed significant correlation between cyclin D1 gene and protein status (Jirstro¨m et al., 2005) . We could not show any significant correlation between amplification of CCND1 and overexpression of the cyclin D1 protein, indicating that the regulation of gene expression and protein levels is a complex process including tight control of cell-cycle proteins together with post-transcriptional and post-translational effects. The analysis of PAK1 amplification in relation to pak1 protein expression did not give reliable information due to small subgroups in the population. Only seven of the PAK1-amplified tumors were available for immunohistochemistry.
Active pak1 has been reported to phosphorylate the ER at Ser305 leading to estrogen-independent activation of the receptor (Wang et al., 2002) . Balasenthil et al. (2004a) showed that activation of the receptor by an amino-acid switch (S305E) upregulates the expression of cyclin D1. Opposite to results from in vitro studies (Holm et al., 2006; Rayala et al., 2006b) , we found no correlation between pak1 and cyclin D1 protein expression. Nor could this link be shown in the ER-positive tumor group. No direct correlation between the expression level of pak1 protein and its kinase activity could be found by Vadlamudi et al. (2000) . The pak1 antibody used in our study did not select for activated pak1, which could be a possible explanation of why we could not see any link between pak1 and cyclin D1 overexpression.
About 40% of the tumors showing normal copy number of the PAK1 gene were positive for pak1 protein expression, suggesting that the pak1 protein is overexpressed not exclusively due to amplification of the gene. Our results indicate that both pak1 expression and PAK1 gene amplification may predict for tamoxifen insensitivity. Growth factor receptors such as ErbB2 11q13 amplification and tamoxifen in breast cancer J Bostner et al (HER2) and epidermal growth factor receptor are potential effectors of pak1. The receptor signaling starts phosphorylation cascades, through for example Rac and Akt signaling, leading to an increase in activated pak1 (Jordan, 2006) . It is well established how pak1 is activated but there are, to our knowledge, no studies showing how the pak1 protein level is raised in breast tumors apart from amplification.
In agreement with Holm et al. (2006) , we show that pak1 cytoplasmic protein overexpression as well as nuclear overexpression is accompanied with decreased tamoxifen sensitivity, indicating tamoxifen resistance. There are reports showing that CCND1 amplification is a more useful prognostic factor than its overexpression, suggesting that there are other genes in the 11q13 chromosomal region contributing to tumor cell selection and poor clinical outcome in breast cancer (Bie`che et al., 2002; Jirstro¨m et al., 2005) and oral squamous-cell carcinoma (Kyomoto et al., 1997; Miyamoto et al., 2003) . We show that amplification of PAK1 may be a better predictor of tamoxifen resistance than amplification of CCND1. Pak1 protein overexpression seems to be a useful tool for predicting tamoxifen resistance. Hence, our results do not discard PAK1 as one of the potential candidate genes in the 11q13 amplicon. Further studies are needed to investigate the role of the pak1 protein and the cyclin D1 proteins in tamoxifen resistance mechanisms.
Materials and methods

Patients
In a previous clinical trial, 679 postmenopausal women with breast cancer diagnosis were randomized to adjuvant chemotherapy or postoperative radiotherapy (Rutqvist and Johansson, 2006) . At the time of diagnosis, the patients had either histological verified lymph node metastases or a tumor diameter exceeding 30 mm. The patients underwent modified radical mastectomy with no preoperative treatment. Surgery was followed by chemotherapy treatment or radiotherapy. Chemotherapy included 6 or 12 courses of CMF given according to the original Milan protocol (cyclophosphamide 100 mg/m 2 orally on day 1-14, methotrexate 40 mg/m 2 intravenously (i.v.) on days 1 and 8, 5-flourouracil 600 mg/m 2 i.v. on days 1 and 8). Radiotherapy was given with the highvoltage technique with a total dose of 46 Gy with 2 Gy per fraction 5 days a week for about 4.5 weeks. The patients were also randomized to either tamoxifen treatment or no adjuvant endocrine therapy using a 2 Â 2 factorial design. Tamoxifen treatment was given postoperatively at a dose of 40 mg/day. The duration of treatment was 2 years. However, a new trial was initiated in 1983; tamoxifen-treated patients who were disease-free at 2 years were randomly allocated to stop treatment or to continue for three more years, that is, a total treatment period of 5 years. Tumors were collected during the years 1976 -1990 . The mean age at surgery was 59 years and the range was 46-70 years. This study included a subset consisting of 224 patients for whom extracted DNA from frozen tumor tissue was still available and for whom the tumor tissue was judged to contain more than 50% of malignant cells. The clinicopathological characteristics in the subset were similar to those in the complete series of 679 patients in the trial, such as a positive lymph node status (90% versus 88%), tumor size larger than 20 mm (60% versus 57%), ER-positive status (70% versus 71%), adjuvant chemotherapy (54% versus 55%) and tamoxifen treatment (50% versus 51%). The study was approved by the regional ethics committee at Karolinska Hospital (Solna).
Amplification analysis DNA was previously extracted from primary tumors (Askmalm et al., 2004) . Analysis of the CCND1 and PAK1 genes were successfully performed in 224 and 214 samples, respectively. Real-time quantitative PCR was performed using 15-20 ng tumor DNA in a 30 ml reaction mixture, with Taq Man PCR core reagent kit (Applied Biosystems, Stockholm, Sweden) containing 5 mM MgCl 2 , 1Â PCR buffer, 0.1 mM dNTP mixture, 0.1 mM of each primer, 0.15 mM probe and 0.025 U/ml AmpliTaq polymerase. Primers and probes were designed to recognize the CCND1 (Scandinavian Gene Synthesis AB, Ko¨ping, Sweden), the PAK1, and the amyloid precursor protein (APP) genes (PAK1 and APP primers were purchased from Sigma-Aldrich Sweden AB (Stockholm, Sweden) and probes from Applied Biosystems. The primer and probe sequences for the genes are presented in Table 4 . All reactions were performed in the ABI Prism 770 Sequence Detection System (Applied Biosystems, Sweden). Reactions were analysed in triplets or pairs. Twenty percent of the patient samples were rerun for verification. Thermal conditions used were 951C for 10 min, 951C for 15 s and 601C for 1 min. Steps two and three were repeated for 50 cycles. A relative kinetic method was applied using a standard curve constructed by the human breast cancer cell line SkBr3. SkBr3 DNA was diluted fourfold giving four different DNA concentrations starting at 60 ng/ml. The APP gene, located on chromosome 21q21, was used as reference gene because no amplifications or deletions have been shown in this location in breast cancer. The target content in tumor samples was quantified using the standard curves and each sample was normalized on the basis of its APP content. The gene copy ratios CCND1/APP and PAK1/APP were calculated. Cutoff levels for amplification were based on the frequency distribution of the gene copy ratios and were set to >1.8 for PAK1 and >3.6 for CCND1, expecting four gene copies or more. Two gene copies were expected at the modal peak in the frequency distribution being 0.9 for PAK1 and 1.8 for CCND1. Amplification of 11q13 was defined as amplification of either CCND1 or PAK1. 
Protein expression
Frozen tissue from 101 breast tumors was available for sectioning and used for immunohistochemistry. The sections were fixed in 4% formalin for 30 min and boiled in microwave oven for 15 min in citrate buffer (pH 6.0). The sections were cooled in room temperature for 20 min, placed in 3% H 2 O 2 in methanol for 5 min, incubated with serum free protein block (Dako, Carpinteria, CA, USA) for 10 min and incubated with rabbit polyclonal Pak1 primary antibody (Cell Signaling Technology, MA, USA) diluted 1:25 in phosphate-buffered saline (PBS) with 0.5% bovine serum albumin (BSA) at 41C in a moisturized chamber for 20 h. The secondary anti-rabbit Dakocytomation Envision þ system labeled with horseradish peroxidase antibody (Dako) was applied. Cells were visualized with 3,3-diaminobenzidin hydrochloride in phosphate buffer and 0.03% H 2 O 2 all diluted in PBS with 0.5% BSA for 10 min and counterstained with hematoxylin. All washing steps were performed in PBS with 0.5% BSA. Pak1 staining intensity was graded as negative, weak, moderate or strong for cytoplasm and nucleus separately. The pak1 antibody has previously been used on breast tumor tissue with similar scoring as in this study (Holm et al., 2006) . All slides were evaluated by two independent observers. A total of 230 tumor samples were previously stained for cyclin D1 protein and nuclear protein expression was graded as weak, moderate or strong (Ahnstro¨m et al., 2005) .
Statistical analysis
For comparing amplification data and protein expression data with prognostic and clinical characteristics, the Pearson w 2 test was used. For ranked variables, Spearman w 2 test for trend was applied. RFS curves were produced using the Kaplan-Meier method. A Cox proportional hazard model was used for the estimation of RRs in univariate and multivariate analysis. P-values o0.05 were considered significant, with the exception of Table 1 , where P-values o0.01 were considered significant to compensate for the effect of multiple comparisons. All statistical analyses were comprised in STATISTICA 7.0 (StatSoft Scandinavia AB, Sweden).
